Mechanism of Action
compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H , K )-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, dexlansoprazole has been…
Indications (6)
Clinical Trials (5)
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Disease (GERD) Participants in the Russian Federation
A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules
Loss of Exclusivity
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 9238029 | Jan 17, 2026Expired | Product | — |
| 8461187 | Jan 17, 2026Expired | Product | — |
| 9011926 | Feb 24, 2026Expired | Product | — |
| 8461187*PED | Jul 17, 2026 | — | |
| 8871273 | Jan 11, 2028 | Product | — |